Endocrine Society Advocacy Win: Congress Increases FY 2026 NIH Funding Last month, Congress finally passed a funding bill for the Department of Health & Human Services for fiscal year (FY) 2026. The bill includes an increase of about $415 million for the National Institutes of Health (NIH), including a $10 million increase for diabetes research, and language the Endocrine Society had advocated for to protect the NIH by limiting a budget maneuver called multi-year funding, prohibiting arbitrary caps to indirect cost rates, requiring grants be paid within five business days, and reclaiming congressional authority over spending. This was a major victory considering that originally the administration proposed a 40% cut to NIH research, cancelled thousands of grants, and proposed restructuring the NIH in ways that would disrupt endocrine research. While the Endocrine Society was not the only group advocating for funding for the NIH, we were one of the most vocal. We worked for a year to achieve our goals and successfully used online advocacy campaigns, Hill Days, visits to congressional offices, and briefings to influence.
Endocrine Society Advocacy Win: Congress Increases FY 2026 NIH Funding Last month, Congress finally passed a funding bill for the Department of Health & Human Services for fiscal year (FY) 2026. The bill includes an increase of about $415 million for the National Institutes of Health (NIH), including a $10 million increase for diabetes research, and language the Endocrine Society had advocated for to protect the NIH by limiting a budget maneuver called multi-year funding, prohibiting arbitrary caps to indirect cost rates, requiring grants be paid within five business days, and reclaiming congressional authority over spending. This was a major victory considering that originally the administration proposed a 40% cut to NIH research, cancelled thousands of grants, and proposed restructuring the NIH in ways that would disrupt endocrine research. While the Endocrine Society was not the only group advocating for funding for the NIH, we were one of the most vocal. We worked for a year to achieve our goals and successfully used online advocacy campaigns, Hill Days, visits to congressional offices, and briefings to influence. While the Endocrine Society was not the only group advocating for funding for the NIH, we were one of the most vocal. We worked for a year to achieve our goals and successfully used online advocacy campaigns, Hill Days, visits to congressional offices, and briefings to influence. In addition, the Endocrine Society convened other professional medical societies, patient advocacy groups to share the same messages. Our last effort was a letter to congressional leadership that we obtained over 140 organizations to join, bolstering our individual efforts. Attention now turns quickly to the upcoming budget cycle for FY 2027. President Trump is expected to release his budget in mid-March, and we anticipate the budget again will include proposals to cut research funding. We will continue to push for steady, sustainable increases in funding for the NIH and we are conducting a virtual Hill Day for Endocrine Society members March 13 to ensure that Congress continues to prioritize and protect NIH. If you are not among the members who are joining us to meet with Congressional staff – stay tuned for ways to add your voice and influence critical funding decisions by sending letters to Congress through our campaigns. Endocrine Society Successfully Advocates for Reauthorization of the SDP and Extending Medicare Telehealth Coverage In February, Congress passed and the president signed into law legislation to reauthorize the Special Diabetes Program (SDP) and extend the Medicare telehealth waivers. The legislation was part of a large appropriations package, which funds several agencies including the Department of Health and Human Services. The new law funds the SDP at $200 million per-program per-year, a $40 million increase for each of the two components of the program. The Society was successful in advocating for this funding increase, and we worked closely with Sens. Susan Collins (R-ME) and Jeanne Shaheen (D-NH), the co-chairs of the Senate Diabetes Caucus, and Reps. Diana DeGette (D-CO) and Michael Bilirakis (R-FL), the co-chairs of the House Diabetes Caucus who championed the program. Endocrinologists are the largest user of telehealth in Medicare, and the Society has been a leading voice in urging Congress to extend these important flexibilities and expand access to telehealth. The Endocrine Society is a leading advocate for the SDP, which is made up of two components. SDP funds type 1 diabetes research being done by the National Institute of Health’s National Institute of Diabetes and Digestive and Kidney Disease (NIDDK). It also supports prevention, education, and treatment programs for indigenous communities across the nation, which is administered through the Indian Health Service. Collins posted a press release on her website celebrating the SDP funding increase, which featured a quote from the Endocrine Society’s Chief Medical Officer, Robert W. Lash, MD. The legislation also extends the Medicare telehealth waivers for two years, which ensures that Medicare beneficiaries can receive care from their physician via telehealth from their home. Endocrinologists are the largest user of telehealth in Medicare, and the Society has been a leading voice in urging Congress to extend these important flexibilities and expand access to telehealth. We thank all of our members who participated in these activities because it made a difference. Senators Continue to Consider Ways to Modernize the NIH Over the last few years and in 2025 particularly, there were several proposals by Congress and the administration to restructure the NIH, including cutting funding by restructuring and reducing the number of NIH Institutes and Centers from 28 to 9. We continue to hear policymakers propose changes to the NIH. Last month, the Senate Committee on Health, Education, Labor, and Pensions (HELP), which oversees the NIH, held a hearing on modernizing it. Jayanta Bhattacharya, director of the NIH, answered questions from members of the committee about topics ranging from drug pricing to gain-of-function research to vaccine scheduling and several policy issues that affect endocrine researchers. Several of the senators on this committee expressed concerns about the impacts of canceled grants and clinical trials on patients and research progress and what the future of the biomedical workforce would look like moving forward. Sen. Susan Collins (R-ME) expressed concerns about how cuts to diversity, equity, and inclusion have negatively impacted women’s health research and research on health disparities and how the current funding environment is negatively influencing early career scientists’ decisions to remain in the research field. Both Sens. Lisa Murkowski (AK-R) and Tammy Baldin (WI-D) raised concerns about gaps in the leadership of the NIH’s Institutes and Centers (IC). The Endocrine Society will continue to advocate for funding for endocrine research and policies that support and protect its researchers and will keep members posted on developments. Baldwin reminded the NIH director about the language she included in the NIH funding bill that the Endocrine Society supported directing the NIH to ensure that external scientists are included in the search process for new IC directors and pressed the director about the consequences of increasing multi-year funding. Sen. Patty Murray (WA-D) pressed Bhattacharya about the impacts of funding cuts on NIH-supported clinical trials and raised concerns about the expiring appointments of Advisory Council members, which are required by law to meet and provide final review of grant applications before grant awards can be distributed. Throughout the hearing, Bhattacharya reiterated his commitment to restoring trust in science, supporting and retaining early-career researchers, and ensuring that the NIH’s focus remains on improving the health of Americans. When asked about the impact of canceled clinical trials on patients, he repeatedly expressed that he had instructed for those patients to receive continuity of care, though that was at the responsibility of the researchers and not the NIH. The Endocrine Society will continue to advocate for funding for endocrine research and policies that support and protect its researchers and will keep members posted on developments. Endocrine Society Hosts Educational Briefing on Obesity & Liver Disease for Congress As part of the Endocrine Society’s policymaker obesity education initiative, we partnered with the American Association for the Study of Liver Diseases (AASLD) to conduct a congressional briefing titled “GLP-1s: A Game Changer for the Treatment of Liver Disease” for congressional staff on January 22. Former Endocrine Society President Dale Abel, MD, PhD, made a trip to the capitol to educate congressional staff on the mechanics of GLP-1s and obesity’s impact on a variety of diseases. The speakers included former Endocrine Society President, Dale Abel, MD, PhD, who educated congressional staff about how GLP-1s work and how obesity affects many diseases, including liver disease. Following the briefing Abel made additional visits to the offices of congressional leadership to discuss obesity and policy options, which helped elevate the Society’s visibility as an authoritative voice in this area. The post Endocrine Society Advocacy In Action – March 2026 appeared first on Endocrine News .